Limonene + beta-phellandrene is not a single defined molecule but an analytical composite label used when GC methods or supplier reports publish the two monoterpenes as one unresolved peak. In the AromaForge archive this combined constituent is currently justified by live oil records such as frankincense and angelica root Serbia, where the source material reports a merged limonene/beta-phellandrene value instead of separate percentages. The strongest evidence here is analytical and identity-focused rather than pharmacology-focused, so this entry should be treated as a chemistry placeholder with transparent limitations, not as a standalone wellness-active ingredient.
Chemical identity and composition
Limonene and beta-phellandrene are both C10H16 monoterpene hydrocarbons, and primary analytical literature notes that beta-phellandrene can elute very close to limonene or even be reported in shared monoterpene peaks depending on method and resolution. In the local archive, the combined constituent is used where the underlying source explicitly reports a single limonene + beta-phellandrene figure instead of separate analytes.
Aroma and practical use
- Use the recorded citrus-like, fresh, peppery, terpenic, citrus descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
frankincense combined peak reporting
The Boswellia differentiation paper reported Boswellia carterii oil with limonene/beta-phellandrene as a combined major fraction rather than separate quantified constituents.
Measured: reported major monoterpene composition
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
angelica root combined peak reporting
A Serbia-focused angelica root report described a major mixture of beta-phellandrene and limonene rather than fully separating those two monoterpenes in the quoted main-compound list.
Measured: major constituents in Serbian root oil
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No standalone CAS number or constituent-specific toxicology program was verified for the combined limonene + beta-phellandrene peak because it is an analytical reporting construct rather than a unique chemical substance.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
When source documents merge these monoterpenes, oxidation-sensitive handling should remain conservative because limonene-rich fractions are well known to form sensitizing oxidation products.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
This record should not be used to make quantitative safety claims for either component unless the underlying analysis separates them.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- This is not a chemically unique constituent entry; it is an archive placeholder for unresolved or pre-merged analytical reporting.
- No direct bioactivity or human safety literature specific to the combined limonene + beta-phellandrene peak was verified in this pass.
- Wherever better source resolution becomes available, this composite entry should ideally be replaced by separate limonene and beta-phellandrene percentages.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.